Table 1.
Characteristics of 136 participants included in the neurocognitive analyses
| Prior syphilis N = 84 |
No prior syphilis N = 52 |
All N = 136 |
|
|---|---|---|---|
| Characteristics | |||
| Female | 21 (25.0%) | 11 (21.2%) | 32 (23.5%) |
| Age, years | 41.6 (8.9) | 41.0 (9.9) | 41.4 (9.3) |
| Education, years | 12.7 (2.6) | 12.4 (2.0) | 12.6 (2.4) |
| Race/ethnicity | |||
| Hispanic | 12 (14.3%) | 2 (3.9%) | 14 (10.3%) |
| White | 23 (27.4%) | 18 (34.6%) | 41 (30.1%) |
| African American | 49 (58.3%) | 32 (61.5%) | 81 (59.6%) |
| HIV risk factor | |||
| MSM | 43 (51.2%) | 28 (54.9%)* | 71 (52.6%) |
| Heterosexual | 41 (48.8%) | 23 (45.1%)* | 64 (47.4%) |
| Injection drug use | 10 (11.9) | 10 (19.2%) | 20 (14.7%) |
| Estimated duration of HIV infection in years | 9.7 (6.6)† | 8.6 (6.1) | 9.2 (6.4) |
| Currently taking ARVs | 54 (64.3%) | 35 (67.3%) | 89 (65.4%) |
| Ever taken ARVs | 67 (79.8%) | 45 (86.5%) | 112 (82.4%) |
| Current CD4, cells/µL | 462 (324)† | 444 (252) | 455 (298) |
| Nadir CD4, cells/µL | 264 (263)‡ | 202 (156) | 240 (229) |
| Log plasma HIV RNA, copies/mL | 2.53 (1.70–4.28) | 2.65 (1.70–4.15) | 2.57 (1.70–4.23) |
| Log CSF HIV RNA, copies/mL | 1.70 (1.70–2.31)† | 1.70 (1.70–2.81) | 1.70 (1.70–2.50) |
| Currently using methamphetamine | 8 (9.6%)† | 3 (5.8%) | 11 (8.1%) |
| Ever used methamphetamine | 21 (25.3%)† | 17 (32.7%) | 38 (28.1%) |
| WRAT-III | 93.1 (14.0) | 90.3 (15.3) | 92.0 (14.5) |
MSM = men who have sex with men; CSF = cerebrospinal fluid; ARV = antiretroviral therapy; WRAT-III = Wide Range Achievement Test, Third Edition Results are expressed as N (percent), mean (standard deviation) and median (interquartile range)
*
N = 51
†
N = 83; one subject whose urine toxicology screen was positive for methamphetamine but who reported that he had never used methamphetamine was not included in the methamphetamine using group
‡
N = 82